2019
25 November, 2019
FluoGuide presentation at Sedermeradagen in Stockholm and Investordagen in Aalborg
At Sedermeradagen in Stockholm, Morten Albrechtsen, CEO and Andreas Kjaer, CSO presented in front of approx. 300 investors. The presentation...
25 November, 2019
FluoGuide A/S: Change of report date
30 November is a Saturday and the report date is therefore changed to Friday, 29 November 2019. For further information, please contact...
20 September, 2019
Presentation of FluoGuide at Life Science Investorkonference Q3 2019
FluoGuide A/S ("FluoGuide", ticker FLUO) was presented at the 18 September at the Life Science Investorkonference in Copenhagen...
7 September, 2019
Presentation of data where FG001 demonstrates dose-depended effectiveness in lightening up glioblastoma in a preclinical model
Despite several decades of effort in improving the standard therapy of Glioblastoma (GBM), an aggressive form of cancer in the brain...
6 September, 2019
Presentation of data where use of FG001 demonstrates improved surgical outcome in metastatic pancreatic cancer compared to standard surgery using only white light
Pancreatic cancer remains one of the deadliest cancers, and the one and five-year survival rates have been reported as 15% and 3% (Carrato...
30 August, 2019
Interim Report For FluoGuide, Second Quarter 2019
Andreas Kjær, responsible for research of FluoGuide comments: "I am very pleased that promising data on the benefit of FG001...
FG001 is initially focused on guiding glioblastoma surgery but has potential in several other cancer indications. One of these indications...
12 August, 2019
FG001 again demonstrates strong data in guiding glioblastoma surgery – accepted for presentation at the World Molecular Imaging Congress 2019
FG001 is the first product from FluoGuide, which lights up the cancer and its invasive growth into the surrounding tissue. It helps...
3 July, 2019
FluoGuide’s ownership to key patent registered
FluoGuide’s first product FG001 lights up the cancer and its invasive growth into the surrounding tissue. FG001 is expected to...